| *Together with |  | (Nasdaq: GAME) |
| Good day, 360 – | Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street! | | | CRNX - Up over 60% in pre-market after Phase 3 trial success | BLRX - Up over 20% in pre after receiving FDA approval for stem cell treatment for patients with Multiple Myeloma | TSLA - Up over 6% in pre after Morgan Stanley upgrade and price target increase | | | *A message on behalf of GameSquare | 🔥 Hot Stock of the Day 🔥 | GameSquare Holdings, Inc (NASDAQ: GAME) | Why do the Dallas Cowboys, Tony Hawk and Ninja all love this $2 stock? | | Many reasons…but after digging into it over the weekend, we're convinced GAME is one of the best opportunities in the whole market right now. | Just a few weeks ago GAME announced their quarterly earnings report. Look at some of the highlights: | 👉Record pipeline and recent contract wins expected to accelerate revenue growth in second half of 2023 | 👉Company reiterates 2023 full-year guidance reflecting sales of $75 to $80 million, and gross margins of 30% - 35% | 👉Recently closed multiple seven figure, multi-year deals with customers across the healthcare, automotive, and CPG sectors | 👉Removed an estimated $5 million of annualized operating costs during the quarter and continues to expect to realize at least $8 million of total annualized cost savings by the end of the year. | Folks, this is a company that is hitting on all cylinders right now, yet the stock has slowly drifted lower and lower during the summer doldrums. | If there has ever been a candidate for a strong reversal, it has to be GAME right now. | Make sure GAME is top of your list 📝 of stocks to look at today – you won't regret it! | Before you ever trade any stock, make sure you understand the risks and rewards involved. Always have a game plan that makes sense for you. Get started on your research by visiting GAME's website. | *Sponsored by GameSquare, please see disclosures below |
|
| | | CRNX- Up over 60% in pre-market after Phase 3 trial success | Crinetics Pharmaceuticals (CRNX) is a clinical stage pharmaceutical company that focuses on the discovery, development and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. | Over the weekend, the company announced that it had achieved the primary and all secondary endpoints in the phase 3 Pathfndr-1 study evaluating treatment of patients with Acromegaly. | Its drug, Paltusotine (an oral, once-daily investigational compound), showed statistical significance at 83% compared to patients taking the placebo at just 4%. | The stock is up over 60% in pre-market after the release of the results. | | The $25.12 area was support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $26.30, $27.30 and then the pre-market high at $29.19. Beyond that, $30, $32 and $34 come into play. | Below $25.12, there is potential support at $23, $22, $20.60, $19 and a gap fill at $15.97. | | BLRX - Up over 20% in pre after receiving FDA approval for stem cell treatment for patients with Multiple Myeloma | BioLineRx Ltd (BLRX) is a pre-commercial-stage biopharmaceutical company that focuses on oncology. | This morning, the company announced that the FDA had approved the company's drug APHEXDA (motixafortide) in combination with Filgrstim to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with Multiple Myeloma. | APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade: | One dosage of APHEXDA plus filgrastim enabled a majority of patients to achieve the collection goal of ≥ 6 million hematopoietic stem cells among a contemporary population of multiple myeloma patients. | Chief Executive Officer of BioLineRx Ltd Philip Serlin stated, "Given the strong efficacy data shown in the GENESIS trial, which included patients who are representative of the current multiple myeloma patient population, we believe APHEXDA will play a critical role in addressing unmet needs and introduce a new treatment paradigm for this challenging cancer." | In this contemporary population, patients in the APHEXDA plus filgrastim arm were able to mobilize more than four times the amount of stem cells with a single dose over a 24-hour period compared with placebo plus filgrastim. | BioLineRx expects to make APHEXDA available later this month. | The stock is up over 20% in pre-market on the news. | | $2.50 has acted as support so far in the pre-market and will be an important level to watch. | Above it, targets to the upside are $2.62, and then the pre-market high at $2.90. Beyond that, $3, $3.20, $3.40, $3.60 and $4 come into play. | Below $2.50, there is potential support at $2.44, $2.20 and a gap to fill at $2.09. | | TSLA - Up over 6% in pre after Morgan Stanley upgrade and price target increase | Tesla Inc (TSLA) designs, develops, manufactures, leases and sells electric vehicles, and energy generation and storage systems in the United States and internationally. | This morning, Morgan Stanley upgraded the stock from neutral-weight to overweight and raising its price target from $250 to $400. Given the size of the investment bank and the number of its clients, this type of upgrade and have an impact on the stock price and we're seeing that with TSLA up 6% in pre-market. | Analyst Adam Jonas cited AI opportunity as part of the reasoning why TSLA could head to over $400 over the next 12 months. | | TSLA is finding support this morning at the $263 area. | Above it the first target is $264 and then the pre-market high at $266.34. Beyond that, $269, $272.90 and $280 come into play. | Below $263, there is potential support at $262, $261.30, $259.50, $256, $254 and a gap fill at $248.50. | | | Economic Calendar | | | | *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | Full Disclosures | *ISSUER-PAID ADVERTISEMENT. RagingBull has been paid ten thousand dollars by ach bank transfer by GameSquare for advertising from a period beginning on september 11, 2023 through september 14 of the same year. RagingBull previously has been paid fifteen thousand dollars by ach bank transfer by GameSquare for advertising from a period beginning on July 12, 2023 through July 14 of the same year. RagingBull has previously been paid twenty thousand dollars by ach bank transfer by GameSquare for advertising from a period beginning on July 5, 2023 through July 7 of the same year. To date, RagingBull has been paid a total of forty-five thousand dollars from GameSquare. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in GameSquare. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of GameSquare, increased trading volume, and possibly an increased share price of the GameSquare securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in GameSquare, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company's financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. | SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. | Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull's business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. | NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," "expects," "projects," "intends," or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec. gov/edgar/searchedgar/companysearch | TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. | WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
| |
|
Post a Comment
Post a Comment